TransPharma Medical, a Lod, Israel-based company developing transdermal drug delivery technology, has completed a Phase Ia trial of its ViaDerm-GLP1 agonist being developed to treat Type 2 diabetes. The study was designed to evaluate two doses of ViaDerm-GLP1 in healthy volunteers, as compared to a subcutaneous injection of Exenatide (Byetta). The results? “Safe and well-tolerated,” says TransPharma, which is company-speak for “it works.” TransPharma’s ViaDerm drug delivery system incorporates a handheld electronic device, which creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch. TransPharma release | ViaDerm overview